Embryo biopsy

Benefit of PGT

Patents who are carriers of single gene mutations can avoid transmitting those disorders to their offspring by testing the embryos and choosing not to transfer those which are affected or carriers.

Patients who have had several miscarriages in the past can benefit from PGT-A for aneuploidy screening by avoiding the transfer of embryos that are aneuploid and will eventually fail to implant. The likelihood of having a trisomic pregnancy increases with advanced maternal age (>38yeara). PGTA-A allows selection of normal embryos at the pre-implantation stage and reduces the chance of detecting abnormal fetal development during an amniocentesis in the second trimester. Patents who failed several in vitro fertilization attempts and and are known to generate good cohorts of embryos might have a high rate of aneuploidy and can benefit by PGT-A. Another group of patients who can benefit from PGT are those who carry translocations, which are detected by karyotyping.